Jump to content
Semaglutide Texas

A field folio of weight, time and outcomes

Bibliography

The trials and review that give the folio its scale, its time spans and its unresolved questions.

Weight and duration

STEP 1 supplies the weight-change comparison. STEP 5 extends the observation period; SURMOUNT-5 supplies a direct tirzepatide comparison. They are gathered in the weight-loss folio.

Disease outcomes and treatment burden

SELECT, FLOW and STEP-HFpEF ask distinct cardiovascular, kidney and symptom questions. SUSTAIN-6 and the safety review also anchor the side-effects account.

Appetite and the alcohol experiment

The rodent neural-pathway study and the human alcohol-use-disorder trial sit together in the appetite folio. Their different study populations are central to the discussion.

  1. Once-Weekly Semaglutide in Adults with Overweight or Obesity ↗
  2. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial ↗
  3. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes ↗
  4. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes ↗
  5. Semaglutide lowers body weight in rodents via distributed neural pathways ↗
  6. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial ↗
  7. Safety of Semaglutide ↗
  8. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes ↗
  9. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity ↗
  10. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity ↗